Overview

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-20

Target enrollment:

Participant gender:

Summary

The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic prostate cancer before radical prostatectomy through clinical trials, thereby identifying an effective treatment for patients with advanced prostate cancer.

Phase:

PHASE2

Details

Lead Sponsor:

baotai Liang

Collaborators:

Subei People's Hospital of Jiangsu Province
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
The First People Hospital of Nantong City

Treatments:

Drug Therapy
Homoharringtonine